Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.60 |
| ▸ | HSD17B1 | P14061 | 2/20 | 0.60 |
| ▸ | MAPT | P10636 | 1/20 | 0.60 |
| ▸ | RECQL | P46063 | 1/20 | 0.60 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.60 |
| ▸ | SRD5A1 | P18405 | 2/20 | 0.55 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | ESR1 | P03372 | 4/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.52 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.52 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.52 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.52 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.52 |
| ▸ | PGR | P06401 | 1/20 | 0.52 |
| ▸ | CNR1 | P21554 | 1/20 | 0.52 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.52 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.52 |
| ▸ | SLC6A3 | Q01959 | 1/20 | 0.52 |
| ▸ | CYP19A1 | P11511 | 2/20 | 0.51 |
| ▸ | STS | P08842 | 5/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25529639 | 1.00 | LMNA (0.60) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL22448486 | 0.84 | LMNA (0.59) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL12826524 | 0.82 | STS (0.61) | ESR1STSCA1CA2CA4 | |
| SCHEMBL788040 | 0.82 | STS (0.47) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL6851953 | 0.81 | LMNA (0.52) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL15705820 | 0.81 | ESR1 (0.55) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL6851908 | 0.80 | LMNA (0.55) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL6568982 | 0.80 | LMNA (0.55) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL25527502 | 0.79 | KDM4E (0.64) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 | |
| SCHEMBL12960472 | 0.79 | LMNA (0.50) | LMNAHSD17B1MAPTRECQLSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6780854-B2 | MALE CONTRACEPTION | AKZO NOBEL NV (NL) | 2004-08-24 | — | — | US | disclosed |
| US-20040059140-A1 | 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile | VAN DER LOUW JAPP (NL) | 2004-03-25 | — | — | US | disclosed |
| EP-1203011-B1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL NV (NL) | 2004-01-02 | — | — | EP | disclosed |
| EP-1343804-A1 | 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE | Akzo Nobel N.V. (NL) | 2003-09-17 | — | — | EP | disclosed |
| US-20030087886-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2003-05-08 | — | — | US | disclosed |
| US-6541465-B2 | Delta 14 derivatives of 19- nortestosterone, useful for the preparation of a medicine for treating androgen insufficiency | AKZO NOBEL N.V. (NL) | 2003-04-01 | — | — | US | disclosed |
| WO-2002048169-A1 | 14(15)-UNSATURATED 15- AND/OR 16- SUBSTITUTED ANDROGENS WITH MIXED ANDROGEN-PROGESTATIONAL PROFILE | AKZO NOBEL N.V. (NL) | 2002-06-20 | — | — | WO | disclosed |
| EP-1203011-A1 | ORALLY ACTIVE ANDROGENS | Akzo Nobel N.V. (NL) | 2002-05-08 | — | — | EP | disclosed |
| US-20020022609-A1 | Orally active androgens | LOOZEN HUBERT JAN JOZEF (NL) | 2002-02-21 | — | — | US | disclosed |
| US-6313108-B1 | TREATING ANDROGEN INSUFFICIENCY | AKZO NOBEL N.V. (NL) | 2001-11-06 | — | — | US | disclosed |
| WO-2001005806-A1 | ORALLY ACTIVE ANDROGENS | AKZO NOBEL N.V. (NL) | 2001-01-25 | — | — | WO | disclosed |
| EP-0411736-B1 | 11-Beta substituted 16-alpha, 17-alpha-methylene-estra-4,9-dien-3-one | SCHERING AG (DE) | 1994-05-04 | — | — | EP | disclosed |
| US-5162312-A | 11β-substituted 16α, 17α-methylene-estra-4,9-dien-3-ones | SCHERING AKTIENGESELLSCHAFT (DE) | 1992-11-10 | — | — | US | disclosed |
| WO-1991001994-A1 | 11β-SUBSTITUTED 16α,17α-METHYLENE-ESTRA-4,9-DIENE-3-ONES | SCHERING AKTIENGESELLSCHAFT BERLIN UND BERGKAMEN (DE) | 1991-02-21 | — | — | WO | disclosed |
| EP-0411736-A1 | 11-Beta substituted 16-alpha, 17-alpha-methylene-estra-4,9-dien-3-one | SCHERING AKTIENGESELLSCHAFT (DE) | 1991-02-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030087886-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | LMNA 2749/4885HSD17B1 15/4885MAPT 4474/4885 |
| US-20020022609-A1 | Orally active androgens | NR5A1, AR, CYP17A1 | LMNA 2728/4885HSD17B1 15/4885MAPT 4467/4885 |
| US-20040059140-A1 | 14(15)-unsaturated 15- and/or 16-substituted androgens with mixed androgen-progrestational profile | HSD17B11, CYP17A1, SHBG | LMNA 2074/4885HSD17B1 8/4885MAPT 1464/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.